Neoplasms of the Esophagus and Stomach

Goldman's Cecil Medicine: Twenty Fourth Edition

Volumn 1, Issue , 2012, Pages 1272-1278

  Rustgi, Anil K ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904372862     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4377-1604-7.00198-6     Document Type: Chapter

References (27)

1. Shaheen NJ, Sharma P, Overholt BF, et al. Radiofrequency ablation in Barrett's esophagus with dysplasia. N Engl J Med 2009, 360:2277-2288.
2. GASTRIC (Global Advanced/Adjuvant Stomach Tumor Reasearch International Collaboration) Group Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010, 303:1729-1737.
3. Sakuramoto S, Sasako M, Yamaguchi T, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007, 357:1810-1820.
4. Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastro esophageal cancer. N Engl J Med 2006, 355:11-20.
5. Macdonald JS, Smalley SR, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725-730.
6. Cunningham D, Starling N, Rao S, et al. Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008, 358:36-46.
7. Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatement of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010, 376:687-697.
8. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008, 372:392-397.
9. Demetri GD, Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006, 368:1329-1338.
10. Ng T, Vezeridis MP Advances in the surgical treatment of esophageal cancer. J Surg Oncol 2010, 101:725-729. Review of technical improvements in surgical resection of esophageal cancer.
11. Paoletti X, Oba K, Burzykowski T, et al. Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis. JAMA 2010, 303:1729-1737. for the GASTRIC (Global Advanced/Adjuvant Stomach Tumor Research International Collaboration) Group, Meta-analysis showing superiority of fluorouracil-based adjuvant chemotherapy compared with surgery alone in reducing mortality.
12. Polk DB, Peek RM Helicobacter pylori: gastric cancer and beyond. Nat Rev Cancer 2010, 10:403-414. Review of mechanisms that regulate the biological interactions of H. pylori with its hosts and that promote carcinogenesis.
13. Spechler SJ, Fitzgerald RC, Prasad GA, et al. History, molecular mechanisms, and endoscopic treatment of Barrett's esophagus. Gastroenterology 2010, 138:854-869. An excellent review of the diagnosis and management of Barrett's esophagus.
14. Wang J, Yu JC, Kang WM, et al. Treatment strategy for early gastric cancer. Surg Oncol 2011, [Epub ahead of print.] Review.
15. Carrato A, Gallego-Plazas J, Guillen-Ponce C Adjuvant therapy of resected gastric cancer is necessary. Semin Oncol 2005, 32:S105-S108. Makes the case for adjuvant chemotherapy.
16. Correa P, Houghton J Carcinogenesis of Helicobacter pylori. Gastroenterology 2007, 133:659-672. Review of the role of H. pylori in gastric carcinogenesis.
17. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002, 347:472-480. Approximately 50% of these tumors respond to the same therapy used for chronic myelogenous leukemia.
18. Hartgrink HH, Jansen EP, van Grieken NC, et al. Gastric cancer. Lancet 2009, 374:477-490. Review.
19. Jiang Y, Ajani JA Multidisciplinary management of gastric cancer. Curr Opin Gastroenterol 2010, 26:640-646. Review emphasizing the benefit of adjuvant chemoradiation with 5-fluorouracil/leucovorin.
20. Kelley JR, Duggan JM Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003, 56:1-9. Estimates that H. pylori accounts for somewhat less than 50% of cases in Western societies.
21. Nguyen S, Rebischung C, Van Ongeval J, et al. Epirubicin-docetaxel in advanced gastric cancer: two phase II studies as second- and first-line treatment. Bull Cancer. 2006, 93:E1-E6. A promising new regimen.
22. Reid BJ, Li X, Galipeau PC, et al. Barrett's oesophagus and oesophageal adenocarcinoma: time for a new synthesis. Nat Rev Cancer 2010, 10:87-101. Review.
23. Rice TW, Rusch VW, Ishwaran H, et al. Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals. Cancer 2010, 116:3763-3773. Development of a new staging system.
24. Tu S, Bhagat G, Cui G, et al. Overexpression of interleukin-1beta induces gastric inflammation and cancer and mobilizes myeloid-derived suppressor cells in mice. Cancer Cell 2008, 14:408-419. This study provides the first link of IL-1beta to gastric cancer in an animal model, underscoring the importance of epidemiological studies that had implicated IL-1beta polymorphisms in gastric cancer.
25. Wagner AD, Grothe W, Behl S, et al. Chemotherapy for advanced gastric cancer. Cochrane Database Syst Rev. 2005;2:CD004064. Meta-analysis indicating that chemotherapy confers a survival benefit over supportive care alone.
26. Wani S, Puli SR, Shaheen NJ, et al. Esophageal adenocarcinoma in Barrett's esophagus after endoscopic ablative therapy: a meta-analysis and systematic review. Am J Gastroenterol 2009, 104:502-513. Review.
27. Wilson KT, Crabtree JE Immunology of Helicobacter pylori: insights into the failure of the immune response and perspectives on vaccine studies. Gastroenterology 2007, 133:288-308. A comprehensive review on the relationship of H. pylori infection and the host immune response. Given that H. pylori is a class I carcinogen according to the World Health Organization, much effort has been expended in the challenging development of vaccines, which have not come to fruition.